J.P. Duffy reflects on international arbitration in the life sciences industry throughout 2021, exploring the increase in emergency arbitration and uptick in manufacturing and distribution disputes, before looking ahead to what 2022 might bring, including the potential proliferation of disputes linked to M&A and expert determination.